2023-05-02 | mRNA Lecture | 2023mRNAVicSeries | 3/4| Exploring the Clinical Trials Landscape

Event Date : 2023-05-02

mRNA Victoria and BioMelbourne Network, hosted a series of four lectures in the first half of 2023 for the RNA community.

These lectures presented an opportunity for leading specialists in the RNA sector to share their knowledge with the local RNA community. 

Lecture Three

The third lecture in the mRNA Victoria and BioMelbourne Network lecture series is focused on clinical trials and associated considerations. The session was chaired by Michelle Gallagher (CEO, Opyl) and included presentations from three speakers followed by a Q&A panel discussion. The intended audience is those that have an interest in the progression of RNA based candidates from preclinical development to clinical trials and the steps taken in order to ensure the appropriate decisions are made for study design and execution. The emphasis was on specific considerations for progressing RNA based candidates to clinic and where the field can progress in the future.

We were fortunate to have three speakers with expertise across a range of facets associated with clinical trial screening, planning and delivery: 

Dr Jason Lickliter, Chief Medical Officer, Nucleus Network: who will talk about Phase 1 clinical trials of mRNA vaccines and therapeutics

Dr Paul Burton, Chief Medical Officer, Moderna: who will speak about the Moderna clinical trials pipeline (USA)

Dr Elizabeth Hartland, Director, Hudson Institute: who will discuss the screening of RNA for potential innate immune response effects

   Duration: 60 mins

   Audio version included:   

   Captioning:   

   Subscription: $ 0

Please click here to view full details of this event.

The free PREVIEW will run for approximately 5 minutes.
You can watch in the full video in FULL screen mode once subscribed.

Please click on the PLAY icon to start the video preview.